Publication Date: January 15, 2015
PaxVax entered the M&A arena last summer, nabbing typhoid vaccine Vivotif from Johnson & Johnson subsidiary Crucell. And it’s not stopping there, CEO Ken Kelley says.
The California company has another specialty travel vaccine deal coming that it’s currently negotiating, the helmsman told FierceVaccines in an interview at this week’s JP Morgan Healthcare Conference. It expects to announce that pact–along with one for a travel med–in the first half of this year.